|Dr. Scott A. Kelly||Chairman, Chief Medical Officer & Head of Bus. Devel.||208.22k||N/A||1970|
|Dr. Nader Z. Pourhassan||CEO, Pres & Director||1.53M||N/A||1963|
|Mr. Michael D. Mulholland CPA, CPA||Chief Financial Officer||445.43k||N/A||1952|
|Dr. Nitya G. Ray||CTO and Head of Process Sciences, Manufacturing & Supply Chain||563k||N/A||1953|
|Dr. Mahboob U. Rahman FACR, M.D., Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Arian Colachis||VP, Gen. Counsel & Sec.||N/A||N/A||1962|
|Dr. Brendan P. Rae||Sr. VP of Bus. Devel.||N/A||N/A||N/A|
|Mr. George Bitar||Head of Quality & Exec. Director||N/A||N/A||N/A|
|Mr. Brian Brothen||Sr. VP of Global Oncology||N/A||N/A||N/A|
|Dr. Denis R. Burger||Scientific Consultant||N/A||N/A||1944|
CytoDyn Inc., a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease. CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
CytoDyn Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.